Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community
Ultsch B, Damm O, Beutels P, Bilcke J, Brueggenjuergen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, et al. (2016)
PHARMACOECONOMICS 34(3): 227-244.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Ultsch, Bernhard;
Damm, OliverUniBi;
Beutels, Philippe;
Bilcke, Joke;
Brueggenjuergen, Bernd;
Gerber-Grote, Andreas;
Greiner, WolfgangUniBi;
Hanquet, Germaine;
Hutubessy, Raymond;
Jit, Mark;
Knol, Mirjam;
von Kries, Ruediger
Alle
Alle
Einrichtung
Abstract / Bemerkung
Incremental cost-effectiveness and cost-utility analyses [health economic evaluations (HEEs)] of vaccines are routinely considered in decision making on immunization in various industrialized countries. While guidelines advocating more standardization of such HEEs (mainly for curative drugs) exist, several immunization-specific aspects (e.g. indirect effects or discounting approach) are still a subject of debate within the scientific community. The objective of this study was to develop a consensus framework for HEEs of vaccines to support the development of national guidelines in Europe. A systematic literature review was conducted to identify prevailing issues related to HEEs of vaccines. Furthermore, European experts in the field of health economics and immunization decision making were nominated and asked to select relevant aspects for discussion. Based on this, a workshop was held with these experts. Aspects on 'mathematical modelling', 'health economics' and 'decision making' were debated in group-work sessions (GWS) to formulate recommendations and/or-if applicable-to state 'pros' and 'contras'. A total of 13 different aspects were identified for modelling and HEE: model selection, time horizon of models, natural disease history, measures of vaccine-induced protection, duration of vaccine-induced protection, indirect effects apart from herd protection, target population, model calibration and validation, handling uncertainty, discounting, health-related quality of life, cost components, and perspectives. For decision making, there were four aspects regarding the purpose and the integration of HEEs of vaccines in decision making as well as the variation of parameters within uncertainty analyses and the reporting of results from HEEs. For each aspect, background information and an expert consensus were formulated. There was consensus that when HEEs are used to prioritize healthcare funding, this should be done in a consistent way across all interventions, including vaccines. However, proper evaluation of vaccines implies using tools that are not commonly used for therapeutic drugs. Due to the complexity of and uncertainties around vaccination, transparency in the documentation of HEEs and during subsequent decision making is essential.
Erscheinungsjahr
2016
Zeitschriftentitel
PHARMACOECONOMICS
Band
34
Ausgabe
3
Seite(n)
227-244
Urheberrecht / Lizenzen
ISSN
1170-7690
eISSN
1179-2027
Page URI
https://pub.uni-bielefeld.de/record/2902118
Zitieren
Ultsch B, Damm O, Beutels P, et al. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS. 2016;34(3):227-244.
Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Brueggenjuergen, B., Gerber-Grote, A., Greiner, W., et al. (2016). Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS, 34(3), 227-244. doi:10.1007/s40273-015-0335-2
Ultsch, Bernhard, Damm, Oliver, Beutels, Philippe, Bilcke, Joke, Brueggenjuergen, Bernd, Gerber-Grote, Andreas, Greiner, Wolfgang, et al. 2016. “Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community”. PHARMACOECONOMICS 34 (3): 227-244.
Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Brueggenjuergen, B., Gerber-Grote, A., Greiner, W., Hanquet, G., Hutubessy, R., Jit, M., et al. (2016). Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS 34, 227-244.
Ultsch, B., et al., 2016. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS, 34(3), p 227-244.
B. Ultsch, et al., “Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community”, PHARMACOECONOMICS, vol. 34, 2016, pp. 227-244.
Ultsch, B., Damm, O., Beutels, P., Bilcke, J., Brueggenjuergen, B., Gerber-Grote, A., Greiner, W., Hanquet, G., Hutubessy, R., Jit, M., Knol, M., von Kries, R., Kuhlmann, A., Levy-Bruhl, D., Perleth, M., Postma, M., Salo, H., Siebert, U., Wasem, J., Wichmann, O.: Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PHARMACOECONOMICS. 34, 227-244 (2016).
Ultsch, Bernhard, Damm, Oliver, Beutels, Philippe, Bilcke, Joke, Brueggenjuergen, Bernd, Gerber-Grote, Andreas, Greiner, Wolfgang, Hanquet, Germaine, Hutubessy, Raymond, Jit, Mark, Knol, Mirjam, von Kries, Ruediger, Kuhlmann, Alexander, Levy-Bruhl, Daniel, Perleth, Matthias, Postma, Maarten, Salo, Heini, Siebert, Uwe, Wasem, Jurgen, and Wichmann, Ole. “Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community”. PHARMACOECONOMICS 34.3 (2016): 227-244.
Daten bereitgestellt von European Bioinformatics Institute (EBI)
17 Zitationen in Europe PMC
Daten bereitgestellt von Europe PubMed Central.
Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study.
Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann O, Karch A, Mikolajczyk RT., BMC Med 16(1), 2018
PMID: 29316913
Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann O, Karch A, Mikolajczyk RT., BMC Med 16(1), 2018
PMID: 29316913
Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
Loganathan T, Ng CW, Lee WS, Hutubessy RCW, Verguet S, Jit M., Health Policy Plan 33(2), 2018
PMID: 29228339
Loganathan T, Ng CW, Lee WS, Hutubessy RCW, Verguet S, Jit M., Health Policy Plan 33(2), 2018
PMID: 29228339
Selection and Interpretation of Scientific Evidence in Preparation for Policy Decisions: A Case Study Regarding Introduction of Rotavirus Vaccine Into National Immunization Programs in Sweden, Norway, Finland, and Denmark.
St-Martin G, Lindstrand A, Sandbu S, Fischer TK., Front Public Health 6(), 2018
PMID: 29868539
St-Martin G, Lindstrand A, Sandbu S, Fischer TK., Front Public Health 6(), 2018
PMID: 29868539
Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
Kuchenbecker U, Chase D, Reichert A, Schiffner-Rohe J, Atwood M., PLoS One 13(5), 2018
PMID: 29795647
Kuchenbecker U, Chase D, Reichert A, Schiffner-Rohe J, Atwood M., PLoS One 13(5), 2018
PMID: 29795647
Evaluation of the Impact of a Rotavirus Vaccine Program on Pediatric Acute Gastroenteritis Hospitalizations: Estimating the Overall Effect Attributable to the Program as a Whole and as a Per-Unit Change in Rotavirus Vaccine Coverage.
Doll MK, Quach C, Buckeridge DL., Am J Epidemiol 187(9), 2018
PMID: 29757352
Doll MK, Quach C, Buckeridge DL., Am J Epidemiol 187(9), 2018
PMID: 29757352
Evaluating Frameworks That Provide Value Measures for Health Care Interventions.
Mandelblatt JS, Ramsey SD, Lieu TA, Phelps CE., Value Health 20(2), 2017
PMID: 28237193
Mandelblatt JS, Ramsey SD, Lieu TA, Phelps CE., Value Health 20(2), 2017
PMID: 28237193
Loss of chance associated with sub-optimal HPV vaccination coverage rate in France.
Uhart M, Adam M, Dahlab A, Bresse X., Papillomavirus Res 3(), 2017
PMID: 28720460
Uhart M, Adam M, Dahlab A, Bresse X., Papillomavirus Res 3(), 2017
PMID: 28720460
Is the impact of childhood influenza vaccination less than expected: a transmission modelling study.
Weidemann F, Remschmidt C, Buda S, Buchholz U, Ultsch B, Wichmann O., BMC Infect Dis 17(1), 2017
PMID: 28399801
Weidemann F, Remschmidt C, Buda S, Buchholz U, Ultsch B, Wichmann O., BMC Infect Dis 17(1), 2017
PMID: 28399801
Vaccines are different: A systematic review of budget impact analyses of vaccines.
Loze PM, Nasciben LB, Sartori AMC, Itria A, Novaes HMD, de Soárez PC., Vaccine 35(21), 2017
PMID: 28427846
Loze PM, Nasciben LB, Sartori AMC, Itria A, Novaes HMD, de Soárez PC., Vaccine 35(21), 2017
PMID: 28427846
Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review.
Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK., Vaccine 35(24), 2017
PMID: 28476628
Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK., Vaccine 35(24), 2017
PMID: 28476628
A systematic review of the health economic consequences of quadrivalent influenza vaccination.
de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ., Expert Rev Pharmacoecon Outcomes Res 17(3), 2017
PMID: 28613092
de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ., Expert Rev Pharmacoecon Outcomes Res 17(3), 2017
PMID: 28613092
2. How is the economic assessment of vaccines performed today?
Standaert B, Rappuoli R., J Mark Access Health Policy 5(1), 2017
PMID: 29785252
Standaert B, Rappuoli R., J Mark Access Health Policy 5(1), 2017
PMID: 29785252
3. How comprehensive can we be in the economic assessment of vaccines?
Standaert B, Rappuoli R., J Mark Access Health Policy 5(1), 2017
PMID: 29785253
Standaert B, Rappuoli R., J Mark Access Health Policy 5(1), 2017
PMID: 29785253
Cost-effectiveness of human papillomavirus vaccination in Germany.
Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W., Cost Eff Resour Alloc 15(), 2017
PMID: 28878573
Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W., Cost Eff Resour Alloc 15(), 2017
PMID: 28878573
Improving accountability in vaccine decision-making.
Timmis JK, Black S, Rappuoli R., Expert Rev Vaccines 16(11), 2017
PMID: 28929818
Timmis JK, Black S, Rappuoli R., Expert Rev Vaccines 16(11), 2017
PMID: 28929818
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L, Joura E, Largeron N, Prager B, Uhart M., BMC Infect Dis 16(), 2016
PMID: 27084683
Boiron L, Joura E, Largeron N, Prager B, Uhart M., BMC Infect Dis 16(), 2016
PMID: 27084683
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C, Eichner M, Welte R, Anastassopoulou A, Van Bellinghen LA, Poulsen Nautrup B, Van Vlaenderen I, Schmidt-Ott R, Schwehm M, Postma M., Pharmacoeconomics 34(12), 2016
PMID: 27647004
Dolk C, Eichner M, Welte R, Anastassopoulou A, Van Bellinghen LA, Poulsen Nautrup B, Van Vlaenderen I, Schmidt-Ott R, Schwehm M, Postma M., Pharmacoeconomics 34(12), 2016
PMID: 27647004
120 References
Daten bereitgestellt von Europe PubMed Central.
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
Comparison of NITAG policies and working processes in selected developed countries
Ricciardi GW, Toumi M, Weil-Olivier C, Ruitenberg EJ, Danko D, Duru G., 2014
Ricciardi GW, Toumi M, Weil-Olivier C, Ruitenberg EJ, Danko D, Duru G., 2014
Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014
Takla A, Wichmann O, Carrillo-Santisteve P, Cotter S, Lévy-Bruhl D, Paradowska-Stankiewicz I., 2015
Takla A, Wichmann O, Carrillo-Santisteve P, Cotter S, Lévy-Bruhl D, Paradowska-Stankiewicz I., 2015
A systematic review of national immunization policy making processes.
Bryson M, Duclos P, Jolly A, Bryson J., Vaccine 28 Suppl 1(), 2010
PMID: 20413000
Bryson M, Duclos P, Jolly A, Bryson J., Vaccine 28 Suppl 1(), 2010
PMID: 20413000
A global look at national Immunization Technical Advisory Groups.
Bryson M, Duclos P, Jolly A, Cakmak N., Vaccine 28 Suppl 1(), 2010
PMID: 20412990
Bryson M, Duclos P, Jolly A, Cakmak N., Vaccine 28 Suppl 1(), 2010
PMID: 20412990
AUTHOR UNKNOWN, 0
AUTHOR UNKNOWN, 0
Estimating influenza vaccine efficacy from challenge and community-based study data.
Basta NE, Halloran ME, Matrajt L, Longini IM Jr., Am. J. Epidemiol. 168(12), 2008
PMID: 18974084
Basta NE, Halloran ME, Matrajt L, Longini IM Jr., Am. J. Epidemiol. 168(12), 2008
PMID: 18974084
Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness.
Bauch CT, Anonychuk AM, Van Effelterre T, Pham BZ, Merid MF., Med Decis Making 29(5), 2009
PMID: 19605882
Bauch CT, Anonychuk AM, Van Effelterre T, Pham BZ, Merid MF., Med Decis Making 29(5), 2009
PMID: 19605882
Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.
Beutels P, Edmunds WJ, Antonanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Pechevis M, Van Doorslaer EK, van Hout BA; Viral Hepatitis Prevention Board., Pharmacoeconomics 20(1), 2002
PMID: 11817988
Beutels P, Edmunds WJ, Antonanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Pechevis M, Van Doorslaer EK, van Hout BA; Viral Hepatitis Prevention Board., Pharmacoeconomics 20(1), 2002
PMID: 11817988
Funding of drugs: do vaccines warrant a different approach?
Beutels P, Scuffham PA, MacIntyre CR., Lancet Infect Dis 8(11), 2008
PMID: 18992409
Beutels P, Scuffham PA, MacIntyre CR., Lancet Infect Dis 8(11), 2008
PMID: 18992409
Methodological issues and new developments in the economic evaluation of vaccines.
Beutels P, Van Doorslaer E, Van Damme P, Hall J., Expert Rev Vaccines 2(5), 2003
PMID: 14711326
Beutels P, Van Doorslaer E, Van Damme P, Hall J., Expert Rev Vaccines 2(5), 2003
PMID: 14711326
The role of health economic analyses in vaccine decision making.
Black S., Vaccine 31(51), 2013
PMID: 23968768
Black S., Vaccine 31(51), 2013
PMID: 23968768
Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.
Brisson M, Edmunds WJ., Med Decis Making 26(5), 2006
PMID: 16997923
Brisson M, Edmunds WJ., Med Decis Making 26(5), 2006
PMID: 16997923
AUTHOR UNKNOWN, 0
Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination.
Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, Annemans L., Vaccine 26 Suppl 5(), 2008
PMID: 18992379
Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, Annemans L., Vaccine 26 Suppl 5(), 2008
PMID: 18992379
Do we fully understand the economic value of vaccines?
Drummond M, Chevat C, Lothgren M., Vaccine 25(32), 2007
PMID: 17629362
Drummond M, Chevat C, Lothgren M., Vaccine 25(32), 2007
PMID: 17629362
Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs.
Duintjer Tebbens RJ, Thompson KM, Hunink MG, Mazzuchi TA, Lewandowski D, Kurowicka D, Cooke RM., Med Decis Making 28(2), 2008
PMID: 18349438
Duintjer Tebbens RJ, Thompson KM, Hunink MG, Mazzuchi TA, Lewandowski D, Kurowicka D, Cooke RM., Med Decis Making 28(2), 2008
PMID: 18349438
Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective.
Edmunds WJ, Medley GF, Nokes DJ., Stat Med 18(23), 1999
PMID: 10602150
Edmunds WJ, Medley GF, Nokes DJ., Stat Med 18(23), 1999
PMID: 10602150
Population- versus cohort-based modelling approaches.
Ethgen O, Standaert B., Pharmacoeconomics 30(3), 2012
PMID: 22283692
Ethgen O, Standaert B., Pharmacoeconomics 30(3), 2012
PMID: 22283692
Study designs for evaluating different efficacy and effectiveness aspects of vaccines.
Halloran ME, Struchiner CJ, Longini IM Jr., Am. J. Epidemiol. 146(10), 1997
PMID: 9384199
Halloran ME, Struchiner CJ, Longini IM Jr., Am. J. Epidemiol. 146(10), 1997
PMID: 9384199
Modelling the epidemiology of infectious diseases for decision analysis: a primer.
Jit M, Brisson M., Pharmacoeconomics 29(5), 2011
PMID: 21504239
Jit M, Brisson M., Pharmacoeconomics 29(5), 2011
PMID: 21504239
AUTHOR UNKNOWN, 0
Methodological concerns with economic evaluations of meningococcal vaccines.
Kauf TL., Pharmacoeconomics 28(6), 2010
PMID: 20465314
Kauf TL., Pharmacoeconomics 28(6), 2010
PMID: 20465314
Health and economic implications of HPV vaccination in the United States.
Kim JJ, Goldie SJ., N. Engl. J. Med. 359(8), 2008
PMID: 18716299
Kim JJ, Goldie SJ., N. Engl. J. Med. 359(8), 2008
PMID: 18716299
Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.
Kim SY, Goldie SJ., Pharmacoeconomics 26(3), 2008
PMID: 18282015
Kim SY, Goldie SJ., Pharmacoeconomics 26(3), 2008
PMID: 18282015
Towards a healthier discount procedure.
Klock RM, Brouwer WB, Annemans LJ, Bos JM, Postma MJ., Expert Rev Pharmacoecon Outcomes Res 5(1), 2005
PMID: 19807560
Klock RM, Brouwer WB, Annemans LJ, Bos JM, Postma MJ., Expert Rev Pharmacoecon Outcomes Res 5(1), 2005
PMID: 19807560
How to estimate productivity costs in economic evaluations.
Krol M, Brouwer W., Pharmacoeconomics 32(4), 2014
PMID: 24504850
Krol M, Brouwer W., Pharmacoeconomics 32(4), 2014
PMID: 24504850
Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models.
Mauskopf J, Talbird S, Standaert B., Expert Rev Pharmacoecon Outcomes Res 12(3), 2012
PMID: 22812559
Mauskopf J, Talbird S, Standaert B., Expert Rev Pharmacoecon Outcomes Res 12(3), 2012
PMID: 22812559
Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts.
O'Mahony JF, de Kok IM, van Rosmalen J, Habbema JD, Brouwer W, van Ballegooijen M., Value Health 14(4), 2011
PMID: 21669368
O'Mahony JF, de Kok IM, van Rosmalen J, Habbema JD, Brouwer W, van Ballegooijen M., Value Health 14(4), 2011
PMID: 21669368
AUTHOR UNKNOWN, 0
Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S., Pharmacoeconomics 24(4), 2006
PMID: 16605282
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S., Pharmacoeconomics 24(4), 2006
PMID: 16605282
Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
Phillips KA, Hotlgrave DR., Am J Prev Med 13(1), 1997
PMID: 9037338
Phillips KA, Hotlgrave DR., Am J Prev Med 13(1), 1997
PMID: 9037338
Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5.
Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M; ISPOR-SMDM Modeling Good Research Practices Task Force., Med Decis Making 32(5), 2012
PMID: 22990086
Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M; ISPOR-SMDM Modeling Good Research Practices Task Force., Med Decis Making 32(5), 2012
PMID: 22990086
Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries.
Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, Scalia Tomba G, Lopalco P, Rizzo C, Merler S, Manfredi P., PLoS ONE 8(4), 2013
PMID: 23613740
Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, Scalia Tomba G, Lopalco P, Rizzo C, Merler S, Manfredi P., PLoS ONE 8(4), 2013
PMID: 23613740
Public health economics of vaccines in the Netherlands: methodological issues and applications
Postma MJ., 2008
Postma MJ., 2008
Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples.
Postma MJ, Westra TA, Quilici S, Largeron N., Expert Rev Vaccines 12(5), 2013
PMID: 23659302
Postma MJ, Westra TA, Quilici S, Largeron N., Expert Rev Vaccines 12(5), 2013
PMID: 23659302
Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.
Pradas-Velasco R, Antonanzas-Villar F, Martinez-Zarate MP., Pharmacoeconomics 26(1), 2008
PMID: 18088158
Pradas-Velasco R, Antonanzas-Villar F, Martinez-Zarate MP., Pharmacoeconomics 26(1), 2008
PMID: 18088158
Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?
Standaert B, Demarteau N, Talbird S, Mauskopf J., Vaccine 28 Suppl 6(), 2010
PMID: 21075268
Standaert B, Demarteau N, Talbird S, Mauskopf J., Vaccine 28 Suppl 6(), 2010
PMID: 21075268
Health economic research on vaccinations and immunisation practices--an introductory primer.
Szucs TD., Vaccine 23(17-18), 2005
PMID: 15755578
Szucs TD., Vaccine 23(17-18), 2005
PMID: 15755578
Discounting: technical issues in economic evaluations of vaccination.
Tasset A, Nguyen VH, Wood S, Amazian K., Vaccine 17 Suppl 3(), 1999
PMID: 10559540
Tasset A, Nguyen VH, Wood S, Amazian K., Vaccine 17 Suppl 3(), 1999
PMID: 10559540
Methods of model calibration: observations from a mathematical model of cervical cancer.
Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein MC., Pharmacoeconomics 28(11), 2010
PMID: 20936883
Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, Weinstein MC., Pharmacoeconomics 28(11), 2010
PMID: 20936883
Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches.
Taylor DC, Pawar V, Kruzikas DT, Gilmore KE, Sanon M, Weinstein MC., Pharmacoeconomics 30(2), 2012
PMID: 22149631
Taylor DC, Pawar V, Kruzikas DT, Gilmore KE, Sanon M, Weinstein MC., Pharmacoeconomics 30(2), 2012
PMID: 22149631
Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.
Van de Velde N, Brisson M, Boily MC., Vaccine 28(33), 2010
PMID: 20573580
Van de Velde N, Brisson M, Boily MC., Vaccine 28(33), 2010
PMID: 20573580
Calibrating models in economic evaluation: a seven-step approach.
Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, Legood R., Pharmacoeconomics 29(1), 2011
PMID: 21142277
Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, Legood R., Pharmacoeconomics 29(1), 2011
PMID: 21142277
WHO Guide for standardisation of economic evaluations of immunization programmes.
Walker DG, Hutubessy R, Beutels P., Vaccine 28(11), 2009
PMID: 19567247
Walker DG, Hutubessy R, Beutels P., Vaccine 28(11), 2009
PMID: 19567247
Recent developments in decision-analytic modelling for economic evaluation.
Weinstein MC., Pharmacoeconomics 24(11), 2006
PMID: 17067190
Weinstein MC., Pharmacoeconomics 24(11), 2006
PMID: 17067190
Economic rate of discount and estimating cost benefit of viral immunisation programmes.
West RR., Rev. Med. Virol. 9(1), 1999
PMID: 10371672
West RR., Rev. Med. Virol. 9(1), 1999
PMID: 10371672
On discounting of health gains from human papillomavirus vaccination: effects of different approaches.
Westra TA, Parouty M, Brouwer WB, Beutels PH, Rogoza RM, Rozenbaum MH, Daemen T, Wilschut JC, Boersma C, Postma MJ., Value Health 15(3), 2012
PMID: 22583467
Westra TA, Parouty M, Brouwer WB, Beutels PH, Rogoza RM, Rozenbaum MH, Daemen T, Wilschut JC, Boersma C, Postma MJ., Value Health 15(3), 2012
PMID: 22583467
Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC).
Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ; ACIP Evidence Based Recommendations Work Group (EBRWG), Temte J, Ahmed F, Beck RL, Calonge N, Campos-Outcalt D, Gidudu J, Huang J, Janes G, Kinsinger L, Langley JM, Marcuse EK, Moyer V, Qaseem A, Schaffner W, Schunemann HJ, Smith JC, Tan LL., Vaccine 29(49), 2011
PMID: 21839794
Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ; ACIP Evidence Based Recommendations Work Group (EBRWG), Temte J, Ahmed F, Beck RL, Calonge N, Campos-Outcalt D, Gidudu J, Huang J, Janes G, Kinsinger L, Langley JM, Marcuse EK, Moyer V, Qaseem A, Schaffner W, Schunemann HJ, Smith JC, Tan LL., Vaccine 29(49), 2011
PMID: 21839794
National decision-making on adopting new vaccines: a systematic review
Burchett HE, Mounier-Jack S, Griffiths UK, Mills AJ., 2012
Burchett HE, Mounier-Jack S, Griffiths UK, Mills AJ., 2012
The role of economic information in decision-making by the Advisory Committee on Immunization Practices.
Dempsey AF, Cowan AE, Stokley S, Messonnier M, Clark SJ, Davis MM., Vaccine 26(42), 2008
PMID: 18708111
Dempsey AF, Cowan AE, Stokley S, Messonnier M, Clark SJ, Davis MM., Vaccine 26(42), 2008
PMID: 18708111
Funding processes for new vaccines: The need for greater understanding of the economic issues
Drummond M., 2008
Drummond M., 2008
An analytical framework for immunization programs in Canada.
Erickson LJ, De Wals P, Farand L., Vaccine 23(19), 2005
PMID: 15752833
Erickson LJ, De Wals P, Farand L., Vaccine 23(19), 2005
PMID: 15752833
The fair innings argument and increasing life spans.
Farrant A., J Med Ethics 35(1), 2009
PMID: 19103945
Farrant A., J Med Ethics 35(1), 2009
PMID: 19103945
The structure and function of immunization advisory committees in Western Europe.
Freed GL., Hum Vaccin 4(4), 2008
PMID: 18398300
Freed GL., Hum Vaccin 4(4), 2008
PMID: 18398300
Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.
Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D., BMC Health Serv Res 8(), 2008
PMID: 19102752
Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D., BMC Health Serv Res 8(), 2008
PMID: 19102752
The United Kingdom Joint Committee on Vaccination and Immunisation.
Hall AJ., Vaccine 28 Suppl 1(), 2010
PMID: 20412998
Hall AJ., Vaccine 28 Suppl 1(), 2010
PMID: 20412998
Criteria for inclusion of vaccinations in public programmes.
Houweling H, Verweij M, Ruitenberg EJ; National Immunisation Programme Review Committee of the Health Council of the Netherlands, Ruitenberg EJ, Roord JJ, Conyn-van Spaendonck MA, van Dalen PJ, van Eden W, de Groot R, de Melker HE, Paulussen TG, Postma MJ, Rumke HC, Severens JL, Stricker BH, Verloove-Vanhorick SP, Vermeulen-Schakel HJ, Verweij M, Voordouw AC, Zaaijer HL, Houweling H., Vaccine 28(17), 2010
PMID: 20189486
Houweling H, Verweij M, Ruitenberg EJ; National Immunisation Programme Review Committee of the Health Council of the Netherlands, Ruitenberg EJ, Roord JJ, Conyn-van Spaendonck MA, van Dalen PJ, van Eden W, de Groot R, de Melker HE, Paulussen TG, Postma MJ, Rumke HC, Severens JL, Stricker BH, Verloove-Vanhorick SP, Vermeulen-Schakel HJ, Verweij M, Voordouw AC, Zaaijer HL, Houweling H., Vaccine 28(17), 2010
PMID: 20189486
AUTHOR UNKNOWN, 0
Canada's National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization.
Ismail SJ, Langley JM, Harris TM, Warshawsky BF, Desai S, FarhangMehr M., Vaccine 28 Suppl 1(), 2010
PMID: 20412999
Ismail SJ, Langley JM, Harris TM, Warshawsky BF, Desai S, FarhangMehr M., Vaccine 28 Suppl 1(), 2010
PMID: 20412999
Are economic evaluations an important tool in vaccine policy decisions?
Jacobs P., Expert Rev Pharmacoecon Outcomes Res 11(5), 2011
PMID: 21958095
Jacobs P., Expert Rev Pharmacoecon Outcomes Res 11(5), 2011
PMID: 21958095
Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.
Jaime Caro J, Eddy DM, Kan H, Kaltz C, Patel B, Eldessouki R, Briggs AH; ISPOR-AMCP-NPC Modeling CER Task Forces., Value Health 17(2), 2014
PMID: 24636375
Jaime Caro J, Eddy DM, Kan H, Kaltz C, Patel B, Eldessouki R, Briggs AH; ISPOR-AMCP-NPC Modeling CER Task Forces., Value Health 17(2), 2014
PMID: 24636375
Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs.
Kimman TG, Boot HJ, Berbers GA, Vermeer-de Bondt PE, Ardine de Wit G, de Melker HE., Vaccine 24(22), 2006
PMID: 16616803
Kimman TG, Boot HJ, Berbers GA, Vermeer-de Bondt PE, Ardine de Wit G, de Melker HE., Vaccine 24(22), 2006
PMID: 16616803
Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses.
Newall AT, Reyes JF, Wood JG, McIntyre P, Menzies R, Beutels P., Vaccine 32(7), 2013
PMID: 24295806
Newall AT, Reyes JF, Wood JG, McIntyre P, Menzies R, Beutels P., Vaccine 32(7), 2013
PMID: 24295806
The Finnish decision-making process to recommend a new vaccine: from vaccine research to vaccination policy
Nohynek H., 2008
Nohynek H., 2008
Criteria for vaccine introduction: results of a DELPHI discussion among international immunisation experts on a stepwise decision-making procedure
Piso B, Zechmeister I, Geiger-Gritsch S., 2011
Piso B, Zechmeister I, Geiger-Gritsch S., 2011
The Federal Vaccination Commission in Switzerland: an officially appointed independent commission ensuring evidence-based recommendations and transparent procedures.
Spicher VM., Vaccine 28 Suppl 1(), 2010
PMID: 20412997
Spicher VM., Vaccine 28 Suppl 1(), 2010
PMID: 20412997
Multiple criteria decision analysis for health technology assessment.
Thokala P, Duenas A., Value Health 15(8), 2012
PMID: 23244821
Thokala P, Duenas A., Value Health 15(8), 2012
PMID: 23244821
The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P., Pharmacoeconomics 23(9), 2005
PMID: 16153131
Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P., Pharmacoeconomics 23(9), 2005
PMID: 16153131
Intergenerational equity: an exploration of the 'fair innings' argument.
Williams A., Health Econ 6(2), 1997
PMID: 9158965
Williams A., Health Econ 6(2), 1997
PMID: 9158965
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.
Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force., Value Health 15(6), 2012
PMID: 22999130
Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force., Value Health 15(6), 2012
PMID: 22999130
A taxonomy of model structures for economic evaluation of health technologies.
Brennan A, Chick SE, Davies R., Health Econ 15(12), 2006
PMID: 16941543
Brennan A, Chick SE, Davies R., Health Econ 15(12), 2006
PMID: 16941543
Active learning to understand infectious disease models and improve policy making.
Willem L, Stijven S, Vladislavleva E, Broeckhove J, Beutels P, Hens N., PLoS Comput. Biol. 10(4), 2014
PMID: 24743387
Willem L, Stijven S, Vladislavleva E, Broeckhove J, Beutels P, Hens N., PLoS Comput. Biol. 10(4), 2014
PMID: 24743387
AUTHOR UNKNOWN, 0
Health and economic impact of the seasonal influenza vaccination programme in England.
Baguelin M, Jit M, Miller E, Edmunds WJ., Vaccine 30(23), 2012
PMID: 22446636
Baguelin M, Jit M, Miller E, Edmunds WJ., Vaccine 30(23), 2012
PMID: 22446636
Economic evaluations of human papillomavirus vaccines.
V Barnabas R, Kulasingam SL., Expert Rev Pharmacoecon Outcomes Res 7(3), 2007
PMID: 20528312
V Barnabas R, Kulasingam SL., Expert Rev Pharmacoecon Outcomes Res 7(3), 2007
PMID: 20528312
Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide.
Bilcke J, Beutels P, Brisson M, Jit M., Med Decis Making 31(4), 2011
PMID: 21653805
Bilcke J, Beutels P, Brisson M, Jit M., Med Decis Making 31(4), 2011
PMID: 21653805
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Rothberg MB, Virapongse A, Smith KJ., Clin. Infect. Dis. 44(10), 2007
PMID: 17443464
Rothberg MB, Virapongse A, Smith KJ., Clin. Infect. Dis. 44(10), 2007
PMID: 17443464
Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia.
Brisson M, Pellissier JM, Levin MJ., Clin. Infect. Dis. 45(11), 2007
PMID: 17990240
Brisson M, Pellissier JM, Levin MJ., Clin. Infect. Dis. 45(11), 2007
PMID: 17990240
The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M, Pellissier JM, Camden S, Quach C, De Wals P., Hum Vaccin 4(3), 2008
PMID: 18382137
Brisson M, Pellissier JM, Camden S, Quach C, De Wals P., Hum Vaccin 4(3), 2008
PMID: 18382137
Seven challenges in modeling vaccine preventable diseases.
Metcalf CJ, Andreasen V, Bjornstad ON, Eames K, Edmunds WJ, Funk S, Hollingsworth TD, Lessler J, Viboud C, Grenfell BT., Epidemics 10(), 2014
PMID: 25843375
Metcalf CJ, Andreasen V, Bjornstad ON, Eames K, Edmunds WJ, Funk S, Hollingsworth TD, Lessler J, Viboud C, Grenfell BT., Epidemics 10(), 2014
PMID: 25843375
Modelling the epidemiological impact of rotavirus vaccination in Germany--a Bayesian approach.
Weidemann F, Dehnert M, Koch J, Wichmann O, Hohle M., Vaccine 32(40), 2014
PMID: 25045820
Weidemann F, Dehnert M, Koch J, Wichmann O, Hohle M., Vaccine 32(40), 2014
PMID: 25045820
Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O., BMC Health Serv Res 13(), 2013
PMID: 24070414
Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O., BMC Health Serv Res 13(), 2013
PMID: 24070414
The cost effectiveness of human papillomavirus vaccines: a systematic review.
Seto K, Marra F, Raymakers A, Marra CA., Drugs 72(5), 2012
PMID: 22413761
Seto K, Marra F, Raymakers A, Marra CA., Drugs 72(5), 2012
PMID: 22413761
The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England
van AJ, Choi YH, Trotter C, Miller E, Jit M., 2012
van AJ, Choi YH, Trotter C, Miller E, Jit M., 2012
Economic evaluation of vaccination programs: the impact of herd-immunity.
Brisson M, Edmunds WJ., Med Decis Making 23(1), 2003
PMID: 12583457
Brisson M, Edmunds WJ., Med Decis Making 23(1), 2003
PMID: 12583457
The cost-effectiveness of varicella vaccination in Canada.
Brisson M, Edmunds WJ., Vaccine 20(7-8), 2002
PMID: 11803072
Brisson M, Edmunds WJ., Vaccine 20(7-8), 2002
PMID: 11803072
The social life of infants in the context of infectious disease transmission; social contacts and mixing patterns of the very young.
van Hoek AJ, Andrews N, Campbell H, Amirthalingam G, Edmunds WJ, Miller E., PLoS ONE 8(10), 2013
PMID: 24146835
van Hoek AJ, Andrews N, Campbell H, Amirthalingam G, Edmunds WJ, Miller E., PLoS ONE 8(10), 2013
PMID: 24146835
Inferring the structure of social contacts from demographic data in the analysis of infectious diseases spread.
Fumanelli L, Ajelli M, Manfredi P, Vespignani A, Merler S., PLoS Comput. Biol. 8(9), 2012
PMID: 23028275
Fumanelli L, Ajelli M, Manfredi P, Vespignani A, Merler S., PLoS Comput. Biol. 8(9), 2012
PMID: 23028275
AUTHOR UNKNOWN, 0
A simplex method for function minimization
Nelder JA, Mead R., 1965
Nelder JA, Mead R., 1965
Multiparameter calibration of a natural history model of cervical cancer.
Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ., Am. J. Epidemiol. 166(2), 2007
PMID: 17526866
Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ., Am. J. Epidemiol. 166(2), 2007
PMID: 17526866
AUTHOR UNKNOWN, 0
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB; ISPOR−SMDM Modeling Good Research Practices Task Force., Value Health 15(6), 2012
PMID: 22999134
Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB; ISPOR−SMDM Modeling Good Research Practices Task Force., Value Health 15(6), 2012
PMID: 22999134
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies., Value Health 6(1), 2003
PMID: 12535234
Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies., Value Health 6(1), 2003
PMID: 12535234
Calibration methods used in cancer simulation models and suggested reporting guidelines.
Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS., Pharmacoeconomics 27(7), 2009
PMID: 19663525
Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS., Pharmacoeconomics 27(7), 2009
PMID: 19663525
Structural and parameter uncertainty in Bayesian cost-effectiveness models.
Jackson CH, Sharples LD, Thompson SG., J R Stat Soc Ser C Appl Stat 59(2), 2010
PMID: 20383261
Jackson CH, Sharples LD, Thompson SG., J R Stat Soc Ser C Appl Stat 59(2), 2010
PMID: 20383261
Accounting for uncertainty in health economic decision models by using model averaging.
Jackson CH, Thompson SG, Sharples LD., J R Stat Soc Ser A Stat Soc 172(2), 2009
PMID: 19381329
Jackson CH, Thompson SG, Sharples LD., J R Stat Soc Ser A Stat Soc 172(2), 2009
PMID: 19381329
A framework for addressing structural uncertainty in decision models.
Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD., Med Decis Making 31(4), 2011
PMID: 21602487
Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD., Med Decis Making 31(4), 2011
PMID: 21602487
Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
Christensen H, Hickman M, Edmunds WJ, Trotter CL., Vaccine 31(23), 2013
PMID: 23566946
Christensen H, Hickman M, Edmunds WJ, Trotter CL., Vaccine 31(23), 2013
PMID: 23566946
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.
Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD; ISPOR-SMDM Modeling Good Research Practices Task Force., Value Health 15(6), 2012
PMID: 22999133
Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD; ISPOR-SMDM Modeling Good Research Practices Task Force., Value Health 15(6), 2012
PMID: 22999133
Health Economic Data Requirements and Availability in the European Union: Results of a Survey Among 10 European Countries.
Skoupa J, Annemans L, Hajek P., Value Health Reg Issues 4(), 2014
PMID: 29702807
Skoupa J, Annemans L, Hajek P., Value Health Reg Issues 4(), 2014
PMID: 29702807
Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review.
Jit M, Mibei W., Vaccine 33(32), 2015
PMID: 26144897
Jit M, Mibei W., Vaccine 33(32), 2015
PMID: 26144897
Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.
Bos JM, Beutels P, Annemans L, Postma MJ., Pharmacoeconomics 22(18), 2004
PMID: 15606224
Bos JM, Beutels P, Annemans L, Postma MJ., Pharmacoeconomics 22(18), 2004
PMID: 15606224
The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany.
Weinke T, Glogger A, Bertrand I, Lukas K., ScientificWorldJournal 2014(), 2014
PMID: 25548792
Weinke T, Glogger A, Bertrand I, Lukas K., ScientificWorldJournal 2014(), 2014
PMID: 25548792
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J, Robertus K., Ann. Intern. Med. 145(5), 2006
PMID: 16954357
Hornberger J, Robertus K., Ann. Intern. Med. 145(5), 2006
PMID: 16954357
Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O., BMC Public Health 15(), 2015
PMID: 26041469
Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O., BMC Public Health 15(), 2015
PMID: 26041469
Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L, Bresse X, Gobbo C, Papageorgiou M., J Med Econ 13(3), 2010
PMID: 20707768
Annemans L, Bresse X, Gobbo C, Papageorgiou M., J Med Econ 13(3), 2010
PMID: 20707768
Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X., Hum Vaccin 7(7), 2011
PMID: 21606685
Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X., Hum Vaccin 7(7), 2011
PMID: 21606685
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Quellen
PMID: 26477039
PubMed | Europe PMC
Suchen in
Google Scholar